Moderna touts UK R&D and manufacturing progress

US mRNA specialist Moderna (Nasdaq: MRNA) demonstrated substantial R&D investment and progress in the UK, two years since signing its strategic partnership with the UK government, at a milestone event at the Harwell Campus in Oxfordshire.

The company noted that the event brought together stakeholders from across the UK life sciences ecosystem to mark the completion of the construction of the Moderna Innovation and Technology Centre (MITC) - a state-of-the-art research, development and manufacturing facility.

Subject to licensure, the first product manufactured at scale is expected to be a COVID-19 vaccine to support the NHS vaccination program. In the event of a pandemic, the site will have the capacity to produce a minimum of 250 million vaccine doses per year, said Moderna.